Inotek Pharmaceuticals Corp (NASDAQ:ITEK) has announced that its plan to explore sale after its most recent trial flopped. The company outlined that the Phase 2 study failed drastically. In this particular study, a number of patients were served with the provider’s drug by the name trabodenoson. They were given this a long with a glaucoma eye drop.
Inotek has disclosed that its large number of patients witnessed major reductions in eye pressure following about some four weeks of treatment. This desirable change wasn’t witnessed by a different group that was served with Xalatan alone.
Some eight weeks later, something crucial was unveiled by researchers. The various patients that had been administered with both drugs did not witness any additional improvements. On the other hand, the ones that had been served with Xalatan recorded improvements.
Some trusted sources have indicated that the provider’s shares have declined by about 39 percent in after-hours trading as of 5 p.m. on Friday to stand at $1.05 per share. Some top analysts have given their take on the matter. They said this was the lowest ever recorded by the renowned provider since it went public.
In January, the 19-employee provider made an announcement outlining that trabodenoson had failed to outperform a placebo. This was after the provider engaged in its Phase 3 trial. Some top researchers revealed that the provider was as a matter of fact targeting spurring production of an important enzyme. It is this enzyme that would help clear proteins that usually clog a section of the human eye that is responsible for draining liquid.
While addressing a press conference recently, one of the company’s top executives said, “There can be no assurance a transaction will result from this process and Inotek does not intend to disclose additional details unless and until it has entered into a specific transaction or otherwise determines that further disclosure is appropriate.”
David Southwell, the CEO of Inotek during a board meeting said that the provider would from now onwards focus on the various interests of its shareholders. They were going to do everything possible to see to it that they in a major way enhanced the shareholder value according to Yahoo.
